Intelligent Mobil Antiretroviral Adherence Coach

描述(申请人提供)：开发的技术：我们建议开发智能移动抗逆转录病毒依从性教练(IMAAC)，这是一个易于使用的移动软件系统，用于提高抗逆转录病毒药物的依从性。IMAAC将在行业标准的个人数字助理(PDA)和手机上运行，它结合了基于认知行为原理、智能交互和推理能力的依从性知识库，以及适合每个单独用户的患者模型。它将学习个人的行为反应模式，并提供已知的替代解决方案，以改善或提高服药依从性。这款产品的创新之处在于，它能够适应个人用户特征，并基于认知-行为原理生成个性化的智能交互指导。这将增强其对长期维持行为改变的效用。在标准的PDA和手机上交付应用程序可以最大限度地降低成本。它还帮助用户维护隐私，因为它不会引起用户携带特殊设备可能会引起的注意。第一阶段的工作将侧重于国际航空咨询委员会的可行性和可接受性。在第二阶段，我们将全面开发该系统，并将其疗效与接受标准护理的对照组患者进行比较。技术/产品/服务的使用：2005年底，美国估计有1,205,969人感染艾滋病毒/艾滋病。到1998年，曾经接受抗逆转录病毒疗法的患者数量增加到71%，然而，在第二次后续采访中，只有53%的患者报告接受了抗逆转录病毒疗法(ART)，这表明尽管在美国接受艾滋病毒护理的大多数人都接受了ART，但继续使用它对相当一部分人来说是有问题的。这是令人不安的，因为有压倒性的证据表明，抗逆转录病毒疗法可以降低与艾滋病毒/艾滋病有关的发病率和死亡率。研究发现，行为干预在提高对复杂的抗逆转录病毒药物治疗方案的依从性方面是成功的。行为干预成功的原因之一是，个人在进行行为干预时得到的反馈和支持，以及支持生活方式改变的信息和策略。以前基于行为的计划的问题是，它们是有时间限制的，而对于感染艾滋病毒的人来说，坚持ART是一项长期的、终生的努力。开发一种基于认知-行为原则的创新系统，可以为个人量身定做，以便该计划真正适应随着时间的推移而发生的个人变化，这可能会促进并保持不同艾滋病毒感染人群的显著遵守。Performigence Corporation的技术提供了基于认知-行为原则表示遵守知识库的能力，并提供智能交互，以便通过行为和生活方式智能理解用户的生理模型并调整指导。IMAAC为个人提供了一种方便和复杂的方法，以获取经过经验验证的艺术坚持方法，这些方法不断根据他们的需求和情况量身定做。对公司的好处：一旦原型开发完成，将争取第二阶段资金，以完成开发并测试系统的有效性。在STTR计划的第一阶段和第二阶段资金支持下，Performigence将能够通过一种将便携性、智能交互、易用性和消费电子产品的低成本与认知行为原则相结合的系统来解决HIV阳性患者对ART的坚持问题。虽然这个系统的设计是为了提高艾滋病毒阳性人群对抗逆转录病毒治疗的依从性，但这个项目对公共卫生的意义相当高，因为这个系统可以很容易地进行修改，以解决严重依赖生活方式变化的其他慢性疾病，如糖尿病和肥胖症。这两种情况都会增加美国所有年龄和种族群体的发病率和死亡率。产品将如何商业化：Performigence的专有软件技术将作为IMAAC开发的基础。该系统将出售给医疗、工业、研究和消费市场。预计IMAAC将被消费者和医生广泛接受和使用。与公共卫生相关：开发一种可以与电话或个人数字助理(PDA)等手持设备一起使用的系统，这种系统可以为个人量身定做，提供激励信息、行为线索、事实信息、互动指导和强化，可能会增加抗逆转录病毒的依从性，从而降低与艾滋病毒/艾滋病相关的发病率和死亡率。此外，该系统将是向医疗提供者提供信息以加强治疗和护理的一种具有成本效益的方法。可以对这种系统进行修改，以满足其他需要改变行为和生活方式的慢性病的需求，使该系统的用途变得广泛。

DESCRIPTION (provided by applicant): Technology Developed: We propose to develop the Intelligent Mobile Antiretroviral Adherence Coach (IMAAC), which is an easy- to-use, mobile software system for enhancing adherence to antiretroviral medication. The IMAAC, which will run on industry standard personal digital assistants (PDAs) and cell phones, combines an adherence knowledgebase founded on cognitive-behavioral principals, intelligent interaction and reasoning capabilities, and a patient model adapted for each individual user. It will learn an individual's behavioral response patterns and provide alternative solutions known to improve or enhance medication adherence. The innovation of this product is its ability to adapt to individual user characteristics and generate personalized intelligent interactive guidance based on cognitive-behavioral principles. This will enhance its utility for long-term maintenance of behavior change. The delivery of the application on standard PDAs and cell phones minimizes costs. It also helps users maintain privacy by not drawing the attention a person may get carrying a specialized device. Phase I efforts will focus on the feasibility and acceptability of the IMAAC. In Phase II, we will fully develop the system and compare its efficacy to a control group of patients receiving standard-of-care. Uses of Technology/Products/Service: At the end of 2005, an estimated 1,205,969 persons in the United States were living with HIV/AIDS. By 1998, the number of patients ever receiving ART increased to 71%, however only 53% of these individuals reported receiving antiretroviral therapy (ART) during a second follow-up interview suggesting that while most individuals receiving care for HIV in the United States have taken ART, continuing its use is problematic for a significant proportion of individuals. This is troubling because there is overwhelming evidence that ART reduces morbidity and mortality associated with HIV/AIDS. Research has found that behavioral interventions are successful at enhancing adherence to complicated antiretroviral medication regimens. One of the reasons behavioral interventions are successful is the feedback and support individuals get while they are engaging in a behavioral intervention along with information and strategies to support lifestyle changes. The problem with previous behaviorally-based programs is that they are time limited, whereas ART adherence is a long-term and life-long endeavor for individuals infected with HIV. Developing an innovative system that is based on cognitive-behavioral principles that can be tailored to an individual so that the program actually adapts to individual changes over time is likely to facilitate and maintain significant adherence among diverse HIV infected populations. Performigence Corporation's technology provides the capability to represent an adherence knowledgebase based on cognitive-behavioral principles and deliver intelligent interaction so that the user's physiological model can be understood and the guidance can be adapted through behavioral and life style intelligence. The IMAAC offers a convenient and sophisticated method for individuals to access empirically validated methods of ART adherence that are continually tailored to their needs and circumstances. Benefit to Company: Once the prototype is developed, Phase II funds will be sought after to complete development and test the efficacy of the system. With Phase I and Phase II funding from the STTR program, Performigence will be able to address ART adherence among HIV-positive individuals with a system that combines portability, intelligent interaction, ease of use, and low cost of consumer electronics with cognitive-behavioral principles. While this system is being designed to improve ART adherence among HIV-positive populations, the public health significance of this project is quite high because this system can be easily modified to address other chronic conditions that rely heavily on lifestyle changes such as diabetes and obesity. Both conditions increase morbidity and mortality across all age and ethnic groups in the United States. How Product Will Be Commercialized: Performigence's proprietary software technology will be used as the foundation for IMAAC development. The system will be sold to medical, industrial, research and consumer markets. It is anticipated that the IMAAC will have widespread uptake and use by consumers as well as physicians. PUBLIC HEALTH RELEVANCE: Developing a system that can be used with hand-held devices like telephones or personal digital assistants (PDAs) that can be tailored to an individual to provide motivational messages, behavioral cues, factual information, interactive guidance and reinforcement would likely increase antiretroviral adherence, thereby reducing morbidity and mortality associated with HIV/AIDS. Additionally, the system would be a cost-effective method to provide information to medical providers to enhance treatment and care. Modifications to such a system could be made to meet the needs of other chronic diseases that require behavioral and lifestyle changes, making the utility of the system wide-ranging.